Strata Critical Medical, Inc. (SRTA)
Official siteHEALTHCARE • MEDICAL CARE FACILITIES • NASDAQ
Market Cap: $492.15M
Last updated: Nov 17, 2026 at 11:06 AM ET
Strata Critical Medical, Inc. (SRTA) Earnings: Report Dates and Results
Strata Critical Medical (SRTA) is expected to report earnings on Mar 1, 2027. In the quarter ended Sep 30, 2026, Strata Critical Medical reported EPS of -$0.05, below the $0.01 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
SRTA has an expected report date of Mar 1, 2027.
SRTA Earnings Call
The latest SRTA earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 21 quarters below that had an estimate, SRTA beat 12, missed 6 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $74.08M, up 50.3% from $49.30M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.05 | $0.01 | -$0.05 - $0.01 | -600.00% | Miss | N/A | 4 | 1 up, 0 down | Nov 3, 2026 | $74.08M |
| Jun 30, 2026 | -$0.01 | -$0.01 | -$0.03 - -$0.01 | 0.00% | In line | N/A | 4 | 1 up, 0 down | Aug 4, 2026 | $72.51M |
| Mar 31, 2026 | $0.04 | -$0.04 | -$0.04 - -$0.04 | +200.00% | Beat | N/A | 1 | 0 up, 0 down | May 6, 2026 | $67.38M |
| Dec 31, 2025 | -$0.12 | $0.06 | N/A | -300.00% | Miss | N/A | 1 | 0 up, 0 down | Mar 3, 2026 | $66.79M |
| Sep 30, 2025 | -$0.12 | -$0.02 | N/A | -500.00% | Miss | N/A | N/A | N/A | Nov 10, 2025 | $49.30M |
| Jun 30, 2025 | -$0.04 | -$0.05 | N/A | +20.00% | Beat | N/A | N/A | N/A | Aug 5, 2025 | $70.80M |
| Mar 31, 2025 | -$0.07 | -$0.10 | N/A | +30.00% | Beat | N/A | N/A | N/A | May 12, 2025 | $54.31M |
| Dec 31, 2024 | -$0.13 | -$0.12 | N/A | -10.60% | Miss | N/A | N/A | N/A | Mar 13, 2025 | $54.36M |
| Sep 30, 2024 | -$0.01 | -$0.02 | N/A | +50.00% | Beat | N/A | N/A | N/A | Nov 12, 2024 | $74.88M |
| Jun 30, 2024 | -$0.06 | -$0.06 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 7, 2024 | $67.94M |
| Mar 31, 2024 | -$0.10 | -$0.11 | N/A | +9.09% | Beat | N/A | N/A | N/A | May 7, 2024 | $51.51M |
| Dec 31, 2023 | -$0.13 | -$0.12 | N/A | -7.92% | Miss | N/A | N/A | N/A | Mar 12, 2024 | $47.48M |
| Sep 30, 2023 | -$0.02 | -$0.06 | N/A | +66.67% | Beat | N/A | N/A | N/A | Nov 8, 2023 | $71.44M |
| Jun 30, 2023 | -$0.09 | -$0.10 | N/A | +10.00% | Beat | N/A | N/A | N/A | Aug 9, 2023 | $60.99M |
| Mar 31, 2023 | -$0.14 | -$0.16 | N/A | +12.50% | Beat | N/A | N/A | N/A | May 11, 2023 | $45.27M |
| Dec 31, 2022 | -$0.22 | -$0.20 | N/A | -10.00% | Miss | N/A | N/A | N/A | Mar 15, 2023 | $38.13M |
| Sep 30, 2022 | -$0.09 | -$0.13 | N/A | +30.77% | Beat | N/A | N/A | N/A | Nov 10, 2022 | $45.72M |
| Jun 30, 2022 | -$0.11 | -$0.19 | N/A | +42.11% | Beat | N/A | N/A | N/A | Aug 9, 2022 | $35.63M |
| Mar 31, 2022 | -$0.15 | -$0.20 | N/A | +25.00% | Beat | N/A | N/A | N/A | May 10, 2022 | $26.63M |
| Sep 30, 2021 | -$0.13 | -$0.14 | N/A | +7.14% | Beat | N/A | N/A | N/A | Dec 20, 2021 | $24.62M |
| Jun 30, 2021 | -$0.47 | -$0.47 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 16, 2021 | $12.95M |
| Mar 31, 2021 | -$0.33 | -$0.03 | N/A | N/A | N/A | -573.0% | N/A | N/A | May 17, 2021 | $9.27M |
| Dec 31, 2020 | -$0.16 | N/A | N/A | N/A | N/A | -328.6% | N/A | N/A | Mar 10, 2021 | $7.99M |
| Sep 30, 2020 | -$0.01 | N/A | N/A | N/A | N/A | -150.0% | N/A | N/A | Nov 10, 2020 | $8.32M |
| Jun 30, 2020 | $0.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 13, 2020 | $3.44M |
| Mar 31, 2020 | $0.07 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 13, 2020 | $6.45M |
| Dec 31, 2019 | $0.07 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 20, 2020 | $5.22M |
| Sep 30, 2019 | $0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 13, 2019 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.35, after -$0.30 the year before. It was $0.09 for the year ended Dec 31, 2019, the oldest of the 6 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.35 | N/A |
| Dec 31, 2024 | -$0.30 | N/A |
| Dec 31, 2023 | -$0.38 | N/A |
| Dec 31, 2022 | -$1.50 | N/A |
| Dec 31, 2020 | -$0.10 | -211.3% |
| Dec 31, 2019 | $0.09 | N/A |
Earnings Calls
The 7 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,100 words across 8 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,126 | 8 | |
| 2026Q2 | Jun 30, 2026 | 4,301 | 6 | |
| 2026Q1 | Mar 31, 2026 | 5,400 | 8 | |
| 2025Q4 | Dec 31, 2025 | 6,053 | 7 | |
| 2025Q3 | Sep 30, 2025 | 3,674 | 6 | |
| 2025Q2 | Jun 30, 2025 | 4,585 | 8 | |
| 2025Q1 | Mar 31, 2025 | 5,543 | 9 |
2026Q3 Earnings Call
Opening remarks
Mathew Schneider CFO of Clinical Services and Vice President of Finance and Investor Relations Thank you for standing by, and welcome to Strata's conference call and webcast for the quarter ended September 30, 2026. We appreciate everyone joining us today. Before we get started, I would like to remind you of the company's forward-looking statement and safe harbor language. Statements made in this conference call that are not historical facts, including statements about future time periods, may be deemed to constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties, and actual future results may differ materially from those expressed or implied by the forward-looking statements. We refer you to our SEC filings, including our annual report on Form 10-K and our quarterly report on Form 10-Q, each as filed with the SEC, for a more detailed discussion of the risk factors that could cause these differences. Any forward-looking statements provided during this conference call are made only as of the date of this call. As stated in our SEC filings, Strata disclaims any intent or obligation to update or revise these forward-looking statements, except as required by law. During today's call, we will also discuss certain non-GAAP financial measures, which we believe may be useful in evaluating our financial performance. A reconciliation of the most directly comparable historical consolidated GAAP financial measures to those historical non-GAAP financial measures is provided in our earnings press release and investor presentation. Our press release, investor presentation, and our Form 10-Q and 10-K filings are available on the Investor Relations section of our website at ir.stratacritical.com. These non-GAAP measures should not be considered in isolation or as a substitute for financial results prepared in accordance with GAAP. Hosting today's call are our co-CEOs, Will Heyburn and Melissa Tomkiel. I'll now turn the call over to Will.
William Heyburn Co-CEO Thank you, Matt, and good morning, everyone. Our strong third quarter results speak for themselves. Q3 was not only ahead of our guidance, but also showed Strata's capability to generate significant cash flow with much higher conversion. As more customers turn to our integrated transplant offering for more of their cases, we are demonstrating continued market share gains in clinical services. This helped drive clinical segment revenue growth of more than 20% sequentially versus Q2 2026. As Melissa will discuss in more detail, our go-to-market is all about creating alignment with our customers' objectives and becoming that trusted long-term partner in a space that's becoming far too complex to go it alone. We saw yet another quarter of sequential margin improvement, driven in large part by achieving our 2027 logistics gross margin target well ahead of plan.
Frequently Asked Questions About SRTA
When is Strata Critical Medical's next earnings date?
Strata Critical Medical's next earnings report is expected for Mar 1, 2027.
Did SRTA beat earnings estimates last quarter?
No. Strata Critical Medical reported EPS of -$0.05 for the quarter ended Sep 30, 2026, below the $0.01 estimate by 600.00%.
What EPS do analysts expect from SRTA next quarter?
The consensus EPS estimate for Strata Critical Medical for the quarter ending Dec 31, 2026 is $0.02 from 6 analysts, with estimates from $0.01 to $0.03.
How often does SRTA beat earnings estimates?
Strata Critical Medical beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -145.07%.
SRTA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors